2003 News Archive
Protherics PLC Interim results
02 December 2003
Protherics plc, the UK biopharmaceutical company, today announces interim results for the six months to 30 September 2003.
FDA grants Orphan Drug designation for Voraxaze
23 August 2003
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for VoraxazeTM, for the treatment of patients at risk of methotrexate toxicity
Notification of major interests in shares
14 August 2003
The Company received a notification from Bradshaw Asset Management Limited on behalf of Victory Capital plc
Notification of major interests in shares
31 July 2003
The Company received a notification from M & G Investment Management Limited on behalf of Prudential plc
Offer Update
24 July 2003
Protherics announces that it has received valid acceptances for more than nine-tenths in nominal value of the Enact Shares
Results of AGM
24 July 2003
The Company is pleased to announce that at the Annual General Meeting which was held on the 24 July 2003
AGM Statement
24 July 2003
At the Annual General Meeting today, Stuart Wallis, Chairman, made the following statement to shareholders.
Director Shareholding
17 July 2003
Protherics plc (Protherics) announces that Dr Mike Peagram, being a director of Protherics, has agreed on 16 July 2003 to acquire 8,360
Protherics awarded Regional Selective Assistance grant
26 June 2003
Protherics plc ("Protherics"), the international biopharmaceuticals company, today announces that it has been awarded a Regional Selective Assistance grant from the Welsh Assembly Government to assist in the development of the company~s FDA approved manufacturing facility in Blaenwaun, Ceredigion.
Appointment of Directors
23 June 2003
Following the offer to acquire the whole of the issued and to be issued share capital of Enact Pharma plc (Enact) being declared unconditional in all respects
Preliminary results 2003
04 June 2003
Protherics PLC (Protherics), the international biopharmaceuticals company, today announces its preliminary results for the year ended 31 March 2003.
Enact Pharma Plc
29 May 2003
Panmure is pleased to announce on behalf of Protherics that the Offer to acquire the entire share capital of Enact has been declared unconditional
Trading update for the year ended 31 March 2003
02 April 2003
Protherics PLC, the UK biopharmaceutical company, today announces its review of trading for the second half of the year ended 31 March 2003. Since reporting its interim results on 3rd December 2002, the Company expects to have traded profitably over the final six months of the year.
2007 News
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
2000 News Archive